Scholarworks Repository

Impact of thiazolidinediones on macular thickness and volume in diabetic eyes

Show simple item record

dc.contributor.author Azar S.
dc.contributor.author El-Mollayess G.M.
dc.contributor.author Al Shaar L.
dc.contributor.author Salti H.I.
dc.contributor.author Bashshur Z.F.
dc.contributor.editor
dc.date Aug-2013
dc.date.accessioned 2017-10-05T15:49:12Z
dc.date.available 2017-10-05T15:49:12Z
dc.date.issued 2013
dc.identifier 10.1016/j.jcjo.2013.04.003
dc.identifier.isbn
dc.identifier.issn 00084182
dc.identifier.uri http://hdl.handle.net/10938/18718
dc.description.abstract Objective: To assess the impact of thiazolidinedione (TZDs) use on macular thickness and volume in patients with diabetes with no macular edema and no diabetic retinopathy (DR) or mild nonproliferative diabetic retinopathy (NPDR). Design: Cross-sectional prospective pilot study. Participants: One hundred twenty patients (60 in each group) were enrolled, but 108 completed the study (59 in the TZD group and 49 in the non-TZD group). Methods: Patients with type II diabetes mellitus were categorized into 2 groups depending on TZD intake. Those with no prior history of treatment for DR were considered for the study. Patients in both groups had assessment of visual acuity and dilated fundus examination. Only patients with no evidence of macular edema and no DR or mild-NPDR were included. Spectral-domain ocular coherence tomography (SD-OCT) was used for measurement of central retinal thickness (CRT) and macular volume. Main outcome measure was difference in mean macular volume and central thickness between the TZD and the non-TZD groups. Results: Baseline demographics and characteristics were well matched between both groups. There was no significant difference in mean CRT of both groups (p = 0.13), but macular volume was significantly lower in the TZD group (p = 0.038). Conclusions: Patients with no macular edema and no DR or mild NPDR on TZDs did not show evidence of fluid retention in the macula on SD-OCT. Larger studies are needed to confirm these results. © 2013 Canadian Ophthalmological Society. Published by Elsevier Inc. All rights reserved.
dc.format.extent
dc.format.extent Pages: (312-316)
dc.language English
dc.publisher Canadian Ophthalmological Society; OTTAWA
dc.relation.ispartof Publication Name: Canadian Journal of Ophthalmology; Publication Year: 2013; Volume: 48; no. 4; Pages: (312-316);
dc.relation.ispartofseries
dc.relation.uri
dc.source Scopus
dc.subject.other
dc.title Impact of thiazolidinediones on macular thickness and volume in diabetic eyes
dc.type Article
dc.contributor.affiliation Azar, S., Department of Internal Medicine, United States
dc.contributor.affiliation El-Mollayess, G.M., Department of Ophthal-mology, United States
dc.contributor.affiliation Al Shaar, L., Clinical Research Unit, American University of Beirut, Beirut, Lebanon
dc.contributor.affiliation Salti, H.I., Department of Ophthal-mology, United States
dc.contributor.affiliation Bashshur, Z.F., Department of Internal Medicine, United States
dc.contributor.authorAddress Bashshur, Z.F.; American University of Beirut-Medical Center, P.O. Box 11-0236-B11, Beirut, Lebanon; email: zb00@aub.edu.lb
dc.contributor.authorCorporate University: American University of Beirut Medical Center; Faculty: Faculty of Medicine; Department: Ophthalmology;
dc.contributor.authorDepartment Ophthalmology
dc.contributor.authorDivision
dc.contributor.authorEmail zb00@aub.edu.lb
dc.contributor.authorFaculty Faculty of Medicine
dc.contributor.authorInitials Azar, S
dc.contributor.authorInitials El-Mollayess, GM
dc.contributor.authorInitials Al Shaar, L
dc.contributor.authorInitials Salti, HI
dc.contributor.authorInitials Bashshur, ZF
dc.contributor.authorOrcidID
dc.contributor.authorReprintAddress Bashshur, ZF (reprint author), Amer Univ Beirut, Med Ctr, POB 11-0236-B11, Beirut, Lebanon.
dc.contributor.authorResearcherID
dc.contributor.authorUniversity American University of Beirut Medical Center
dc.description.cited Bishop-Bailey D, 1999, J BIOL CHEM, V274, P17042, DOI 10.1074-jbc.274.24.17042; Brown JC, 2004, ARCH OPHTHALMOL-CHIC, V122, P330, DOI 10.1001-archopht.122.3.330; Bunce C, 2008, EYE, V22, P905, DOI 10.1038-sj.eye.6702767; Chaturvedi N, 2008, LANCET, V372, P1394, DOI 10.1016-S0140-6736(08)61412-9; Colucciello M, 2005, ARCH OPHTHALMOL-CHIC, V123, P1273, DOI 10.1001-archopht.123.9.1273; Deshpande AD, 2008, PHYS THER, V88, P1254, DOI 10.2522-ptj.20080020; Fong DS, 2009, AM J OPHTHALMOL, V147, P583, DOI 10.1016-j.ajo.2008.10.016; Forooghian F, 2008, INVEST OPHTH VIS SCI, V49, P4290, DOI 10.1167-iovs.08-2113; Ishizuka T, 1998, DIABETES, V47, P1494, DOI 10.2337-diabetes.47.9.1494; Keech AC, 2007, LANCET, V370, P1687, DOI 10.1016-S0140-6736(07)61607-9; Kim J, 2007, EXP EYE RES, V84, P886, DOI 10.1016-j.exer.2007.01.009; Klein R, 2009, OPHTHALMOLOGY, V116, P497, DOI 10.1016-j.ophtha.2008.10.016; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953; Liazos E, 2008, DIABETIC MED, V25, P860, DOI 10.1111-j.1464-5491.2008.02491.x; Marx N, 1999, ARTERIOSCL THROM VAS, V19, P546; Mauer M, 2009, NEW ENGL J MED, V361, P40, DOI 10.1056-NEJMoa0808400; Mudaliar Sunder, 2003, Endocr Pract, V9, P406; Murata T, 2001, ARCH OPHTHALMOL-CHIC, V119, P709; Niemeyer NV, 2002, PHARMACOTHERAPY, V22, P924, DOI 10.1592-phco.22.11.924.33626; Nolan JJ, 2000, DIABETIC MED, V17, P287, DOI 10.1046-j.1464-5491.2000.00269.x; Pasceri V, 2000, CIRCULATION, V101, P235; Paulus YM, 2009, GERIATRICS, V64, P16; Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038-34178; Ryan EH, 2006, RETINA-J RET VIT DIS, V26, P562, DOI 10.1097-00006982-200605000-00011; Satoh H, 1999, BIOCHEM BIOPH RES CO, V254, P757, DOI 10.1006-bbrc.1998.0126; Shah ND, 2010, NEW ENGL J MED, V363, P2081, DOI 10.1056-NEJMp1011042; Shu H, 2000, BIOCHEM BIOPH RES CO, V267, P345, DOI 10.1006-bbrc.1999.1968; Sjolie AK, 2008, LANCET, V372, P1385, DOI 10.1016-S0140-6736(08)61411-7; Song WK, 2010, INVEST OPHTH VIS SCI, V51, P3913, DOI 10.1167-iovs.09-4189; Stephenson J, 2011, JAMA-J AM MED ASSOC, V306, P143, DOI 10.1001-jama.2011.939; Stumvoll M, 2002, ANN MED, V34, P217, DOI 10.1080-713782132; Tatti P, 2008, CLIN DRUG INVEST, V28, P327; SHAMOON H, 1993, NEW ENGL J MED, V329, P977; UK Prospective Diabetes Study Group, 1998, BMJ-BRIT MED J, V317, P703, DOI DOI 10.1136-BMJ.317.7160.703; Tarbett Aaron K, 2011, J Diabetes Sci Technol, V5, P945; Wiesenberg I, 1998, MOL PHARMACOL, V53, P1131; Xin XH, 1999, J BIOL CHEM, V274, P9116, DOI 10.1074-jbc.274.13.9116; Yki-Jarvinen H, 2004, NEW ENGL J MED, V351, P1106, DOI 10.1056-NEJMra041001; Young PW, 1998, J PHARMACOL EXP THER, V284, P751
dc.description.citedCount
dc.description.citedTotWOSCount 1
dc.description.citedWOSCount 1
dc.format.extentCount 5
dc.identifier.articleNo
dc.identifier.coden CAJOB
dc.identifier.pubmedID 23931472
dc.identifier.scopusID 84888345786
dc.identifier.url
dc.publisher.address 1525 CARLING AVE SUITE 610, OTTAWA, ONTARIO K1Z 8R9, CANADA
dc.relation.ispartofConference
dc.relation.ispartofConferenceCode
dc.relation.ispartofConferenceDate
dc.relation.ispartofConferenceHosting
dc.relation.ispartofConferenceLoc
dc.relation.ispartofConferenceSponsor
dc.relation.ispartofConferenceTitle
dc.relation.ispartofFundingAgency
dc.relation.ispartOfISOAbbr Can. J. Opthalmol.-J. Can. Opthalmol.
dc.relation.ispartOfIssue 4
dc.relation.ispartOfPart
dc.relation.ispartofPubTitle Canadian Journal of Ophthalmology
dc.relation.ispartofPubTitleAbbr Can. J. Ophthalmol.
dc.relation.ispartOfSpecialIssue
dc.relation.ispartOfSuppl
dc.relation.ispartOfVolume 48
dc.source.ID WOS:000331148900034
dc.type.publication Journal
dc.subject.otherAuthKeyword
dc.subject.otherChemCAS pioglitazone, 105355-27-9, 111025-46-8
dc.subject.otherChemCAS rosiglitazone, 122320-73-4, 155141-29-0
dc.subject.otherIndex 2,4 thiazolidinedione derivative
dc.subject.otherIndex oral antidiabetic agent
dc.subject.otherIndex pioglitazone
dc.subject.otherIndex rosiglitazone
dc.subject.otherIndex adult
dc.subject.otherIndex article
dc.subject.otherIndex central retinal thickness
dc.subject.otherIndex computed tomography scanner
dc.subject.otherIndex controlled clinical trial
dc.subject.otherIndex controlled study
dc.subject.otherIndex coronary artery disease
dc.subject.otherIndex cross-sectional study
dc.subject.otherIndex diabetic retinopathy
dc.subject.otherIndex eye fundus
dc.subject.otherIndex female
dc.subject.otherIndex human
dc.subject.otherIndex macular thickness
dc.subject.otherIndex macular volume
dc.subject.otherIndex major clinical study
dc.subject.otherIndex male
dc.subject.otherIndex microalbuminuria
dc.subject.otherIndex non insulin dependent diabetes mellitus
dc.subject.otherIndex nonproliferative diabetic retinopathy
dc.subject.otherIndex outcome assessment
dc.subject.otherIndex peripheral edema
dc.subject.otherIndex pilot study
dc.subject.otherIndex prospective study
dc.subject.otherIndex retina macula edema
dc.subject.otherIndex spectral domain optical coherence tomography
dc.subject.otherIndex visual acuity
dc.subject.otherIndex visual system parameters
dc.subject.otherKeywordPlus ACTIVATED RECEPTOR-GAMMA
dc.subject.otherKeywordPlus OPTICAL COHERENCE TOMOGRAPHY
dc.subject.otherKeywordPlus PPAR-GAMMA
dc.subject.otherKeywordPlus ANTIDIABETIC THIAZOLIDINEDIONE
dc.subject.otherKeywordPlus ENDOTHELIAL-CELLS
dc.subject.otherKeywordPlus CONTROLLED-TRIAL
dc.subject.otherKeywordPlus IN-VITRO
dc.subject.otherKeywordPlus EDEMA
dc.subject.otherKeywordPlus ROSIGLITAZONE
dc.subject.otherKeywordPlus RETINOPATHY
dc.subject.otherWOS Ophthalmology


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search Scholarworks


Browse

My Account